Οκτ62015Βιβλιογραφικά δεδομέναΓια να δείτε το άρθρο πιέστε εδώ Κατηγορία Βιβλιογραφικά δεδομένα6 Οκτωβρίου 2015 Μοιραστείτε το! Share on FacebookShare on Facebook Share on XShare on X Share on LinkedInShare on LinkedIn Share on WhatsAppShare on WhatsApp Post navigationΠροηγούμενοPrevious post:Statin use and non-alcoholic steatohepatitis in at risk individualsΕπόμενοNext post:Εκπαιδευτική Διημερίδα Ε.Ε.Μ.Η. Μάιος 2016Σχετικά ΆρθραDynamics of liver stiffness measurement and clinical course of primary biliary cholangitis21 Αυγούστου 2024We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?1 Αυγούστου 2024Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study29 Ιουνίου 2024Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)3 Ιουνίου 2024Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis21 Μαΐου 2024Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial8 Μαΐου 2024
Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis21 Αυγούστου 2024
We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?1 Αυγούστου 2024
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study29 Ιουνίου 2024
Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)3 Ιουνίου 2024
Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis21 Μαΐου 2024
Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial8 Μαΐου 2024
